Polycythemia natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
Homa Najafi (talk | contribs) No edit summary |
|||
| (4 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Polycythemia}} | {{Polycythemia}} | ||
{{CMG}} {{AE}}{{Debduti}} | {{CMG}} ; {{AE}} {{Debduti}}; {{ZO}} | ||
==Overview== | ==Overview== | ||
| Line 16: | Line 16: | ||
===Natural History=== | ===Natural History=== | ||
*The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___. | |||
*The symptoms of (disease name) typically develop ___ years after exposure to ___. | *The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___. | ||
*The symptoms of (disease name) typically develop ___ years after exposure to ___. | |||
*If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3]. | *If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3]. | ||
===Complications=== | ===Complications=== | ||
*Common complications of [ | |||
**[ | *Common [[complications]] of [[polycythemia vera]] include:<ref name="pmid31151982">{{cite journal| author=Spivak JL| title=How I treat polycythemia vera. | journal=Blood | year= 2019 | volume= 134 | issue= 4 | pages= 341-352 | pmid=31151982 | doi=10.1182/blood.2018834044 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31151982 }} </ref> | ||
**[ | **Post-PV [[myelofibrosis]] (PPMF) in 10% of PV patients. | ||
**[[Leukemic]] transformation, the most serious [[complication]], can develop in [[Chronic (medicine)|chronic]] phase, but more frequently during PPMF, spontaneously or associated with [[chemotherapy]] or [[irradiation]], particularly in patients age ≥60 years. | |||
===Prognosis=== | ===Prognosis=== | ||
*Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [--]%. | |||
*[[Prognosis]] is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [--]%. | |||
*Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent. | *Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent. | ||
*The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy]. | *The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy]. | ||
| Line 39: | Line 41: | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Blood disorders]] | |||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
{{WS}} | {{WS}} | ||
{{WH}} | {{WH}} | ||
Latest revision as of 02:01, 3 March 2021
|
Polycythemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Polycythemia natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Polycythemia natural history, complications and prognosis |
|
FDA on Polycythemia natural history, complications and prognosis |
|
CDC on Polycythemia natural history, complications and prognosis |
|
Polycythemia natural history, complications and prognosis in the news |
|
Blogs on Polycythemia natural history, complications and prognosis |
|
Risk calculators and risk factors for Polycythemia natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Debduti Mukhopadhyay, M.B.B.S[2]; Zaida Obeidat, M.D.
Overview
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
OR
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
OR
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
Natural History, Complications, and Prognosis
Natural History
- The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___.
- The symptoms of (disease name) typically develop ___ years after exposure to ___.
- If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
Complications
- Common complications of polycythemia vera include:[1]
- Post-PV myelofibrosis (PPMF) in 10% of PV patients.
- Leukemic transformation, the most serious complication, can develop in chronic phase, but more frequently during PPMF, spontaneously or associated with chemotherapy or irradiation, particularly in patients age ≥60 years.
Prognosis
- Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [--]%.
- Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
- The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
- [Subtype of disease/malignancy] is associated with the most favorable prognosis.
- The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.
References
- ↑ Spivak JL (2019). "How I treat polycythemia vera". Blood. 134 (4): 341–352. doi:10.1182/blood.2018834044. PMID 31151982.